Company Overview
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical entity dedicated to the artificial intelligence and machine learning-driven analysis of medical and healthcare datasets within the United States. The company provides the bfLEAP platform, an analytical tool designed to facilitate the examination of preclinical data sets. This organization functions within the Healthcare sector, specifically categorized under the Health Information Services industry, which implies a focus on processing and interpreting medical data rather than direct pharmaceutical manufacturing. The company currently maintains a market capitalization of $6.44M and employs 9 individuals to support its operations. With an annual revenue of $116,670, the company's financial scale is indicative of a very small-cap status, suggesting it is an early-stage venture with limited market penetration relative to established industry peers. The combination of a minimal workforce and modest revenue stream highlights that the business is in a development phase where resources are likely concentrated on product maturation and market expansion rather than profit generation or large-scale deployment.
Financial Health
The company reported revenue of $116,670 over the trailing twelve-month period, yet this revenue generated a net income of $-6,498,068, revealing a significant disconnect between top-line activity and bottom-line profitability. The EBITDA stands at $-6,592,911, which further underscores that the company is burning cash to fund its operational and developmental expenses. The free cash flow is recorded at $-3,317,732, indicating that the company is utilizing its liquid assets to finance its current operations and growth initiatives rather than generating cash reserves. The gross margin is 18.8%, which suggests that the cost of goods sold consumes a substantial portion of revenue, while the operating margin of -5652.4% and profit margin of 0.0% demonstrate that overhead costs and other operational expenses are far exceeding revenue generation. The company holds cash of $2.18M against a debt level listed as N/A, meaning there is no reported debt to offset against its cash position. Although the debt-to-equity ratio is listed as N/A, the absence of reported debt combined with a positive cash balance suggests a conservative balance sheet structure free from leverage burdens. The current ratio is 3.85, which indicates a strong short-term liquidity position where current assets significantly exceed current liabilities. The return on equity is -183.0% and the return on assets is -98.6%, metrics that reveal that management has not yet achieved positive capital efficiency and that the company is currently destroying shareholder value and utilizing assets unprofitably.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is also N/A, implying that the market cannot value the stock based on traditional earnings multiples at this time. The price-to-book ratio is 2.72, which indicates that the market is valuing the company at a premium of 2.72 times its book value, suggesting investors are pricing in future growth potential or intangible assets not reflected on the balance sheet. The price-to-sales ratio is 55.18, a high multiple that suggests the market expects significant future expansion, while the EV/EBITDA stands at -0.65, reflecting negative enterprise value multiples typical of pre-profitability biotech and AI firms. The stock has traded between a 52-week high of $2.20 and a 52-week low of $0.42, with the current price position needing to be contextualized within this wide range to understand recent volatility. The beta value is 0.71, which means the stock price exhibits lower volatility relative to the broader market, moving approximately 29% less than the market index on average during periods of fluctuation.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is N/A, indicating that there is insufficient historical data to calculate consistent growth rates or determine if earnings are growing faster or slower than revenue. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. As a non-dividend payer, the company reinvests its limited earnings and cash reserves entirely back into the business to fund research and development activities rather than providing income to investors. The overall growth and income profile is characterized by a lack of historical growth metrics and no current income generation, relying instead on the conversion of cash reserves into future product capabilities to drive eventual market entry.